Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

被引：0
|
作者：
Bruera, Gemma
Massacese, Silvia
Pepe, Francesco
Malapelle, Umberto
Dal Mas, Antonella
Ciacco, Eugenio
Calvisi, Giuseppe
Marchetti, Paolo
Troncone, Giancarlo
Simmaco, Maurizio
Ricevuto, Enrico
机构：
[1] Univ Aquila, S Salvatore Hosp, Dept Biotechnol & Appl Clin Sci, Oncol Territorial Care,Oncol Network ASL1 Abruzzo, Laquila, Italy
[2] S Salvatore Hosp, Pharm Unit, Oncol Network ASL1 Abruzzo, Laquila, Italy
[3] Univ Federico II, Dept Publ Hlth, Naples, Italy
[4] S Salvatore Hosp, Oncol Network ASL1 Abruzzo, Pathol, Laquila, Italy
[5] Sapienza Univ Rome, S Andrea Hosp, Rome, Italy
[6] S Andrea Hosp, Adv Mol Diagnost, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e15517
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15517
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
    Cheng, Ann-Lii
    Cornelio, Gerardo
    Shen, Lin
    Price, Timothy
    Yang, Tsai-Sheng
    Chung, Ik Joo
    Dai, Guang-Hai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas
    Gibbs, Peter
    Wang, Xiuwen
    Doval, Dinesh Chandra
    Oh, Seung-Taek
    Shim, Byoung Yong
    Gorospe, Charity
    Wang, Hwei-Ming
    Sirachainan, Ekaphop
    Hill, Andrew
    Suh, Kwang Wook
    Beier, Frank
    Chatterjee, Sudipto
    Lim, Robert
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E73 - E88
  • [42] A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)
    Ding, K.
    Liu, Y.
    Du, J.
    Zhu, Y.
    Xu, D.
    Li, J.
    Liao, X.
    He, J.
    Wang, J.
    Liu, Z.
    Sun, L.
    Xiao, Q.
    Wang, J.
    Cao, H.
    Cai, Y.
    Cai, C.
    Jin, Z.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S545 - S545
  • [43] mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109)
    Geissler, M.
    Klingler, T.
    Riera-Knorrenschield, J.
    Tannapfel, A.
    Seufferlein, T.
    Held, S.
    Florschuetz, A.
    Kanzler, S.
    Heinemann, V.
    Reinacher-Schick, A.
    Martens, U.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109).
    Geissler, Michael
    Riera-Knorrenschild, Jorge
    Tannapfel, Andrea
    Greeve, Jobst
    Florschutz, Axel
    Wessendorf, Swen
    Seufferlein, Thomas
    Kanzler, Stephan
    Held, Swantje
    Heinemann, Volker
    Reinacher-Schick, Anke C.
    Martens, Uwe Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109)
    Geissler, M.
    Martens, U.
    Knorrenschild, J. R.
    Greeve, J.
    Florschuetz, A.
    Tannapfel, A.
    Moennich, H.
    Ettrich, T.
    Kanzler, S.
    Buechner-Steudel, P.
    Heinemann, V.
    Held, S.
    Reinacher-Schick, A.
    Hebart, H.
    Atzpodien, J.
    Egger, M.
    Lindig, U.
    Mueller, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 123 - 123
  • [46] mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109)
    Geissler, M.
    Martens, U. M.
    Knorrenschield, R.
    Greeve, J.
    Florschuetz, A.
    Tannapfel, A.
    Wessendorf, S.
    Seufferlein, T.
    Kanzler, S.
    Heinemann, V.
    Held, S.
    Reinacher-Schick, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study
    Moretto, Roberto
    Battaglin, Francesca
    Antoniotti, Carlotta
    Buggin, Federica
    Delliponti, Laura
    Bergamo, Francesca
    Cremolini, Chiara
    Brunello, Antonella
    Schirripa, Marta
    Menichetti, Alice
    Salvatore, Lisa
    Marsico, Valentina Angela
    Rossini, Daniele
    Rumano', Laura
    Marmorino, Federica
    Falcone, Alfredo
    Zagonel, Vittorina
    Loupakis, Fotios
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
    Martini, G.
    Ciardiello, D.
    Famiglietti, V.
    Rossini, D.
    Antoniotti, C.
    Troiani, T.
    Napolitano, S.
    Esposito, L.
    Latiano, T. P.
    Maiello, E.
    Del Re, M.
    Lonardi, S.
    Aprile, G.
    Santini, D.
    Masi, G.
    Avallone, A.
    Normanno, N.
    Pietrantonio, F.
    Pinto, C.
    Ciardiello, F.
    Cremolini, C.
    Martinelli, E.
    CANCER MEDICINE, 2023, 12 (08): : 9392 - 9400
  • [49] mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): an update of the randomized phase II VOLFI trial of the AIO (AIO-KRK0109)
    Geissler, M.
    Klingler, T.
    Tannapfel, A.
    Riera-Knorrenschild, J.
    Held, S.
    Greeve, J.
    Wessendorf, S.
    Seufferlein, T.
    Kanzler, S.
    Heinemann, V.
    Reinacher-Schick, A.
    Martens, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 120 - 120
  • [50] NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
    Jacobs, Samuel A.
    George, Thomas J.
    Kolevska, Tatjana
    Wade, James Lloyd
    Zera, Richard
    Buchschacher, Gary L.
    Al Baghdadi, Tareq
    Shipstone, Asheesh
    Lin, Daniel
    Yothers, Greg
    Pogue-Geile, Katherine L.
    Huggins-Puhalla, Shannon Leigh
    Allegra, Carmen Joseph
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345